{"id":"erlotinib-gefitinib","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Rash/acneiform dermatitis"},{"rate":"30-50","effect":"Diarrhea"},{"rate":"20-40","effect":"Nausea"},{"rate":"10-20","effect":"Vomiting"},{"rate":"15-30","effect":"Fatigue"},{"rate":"10-20","effect":"Anorexia"},{"rate":"1-3","effect":"Interstitial lung disease"}]},"_chembl":{"chemblId":"CHEMBL939","moleculeType":"Small molecule","molecularWeight":"446.91"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs competitively inhibit EGFR tyrosine kinase activity, preventing autophosphorylation and downstream signaling through the MAPK and PI3K/AKT pathways. This leads to cell cycle arrest and apoptosis in EGFR-dependent tumors, particularly those with activating EGFR mutations. They are selective for EGFR over other receptor tyrosine kinases.","oneSentence":"Erlotinib and gefitinib are tyrosine kinase inhibitors that block epidermal growth factor receptor (EGFR) signaling to inhibit cancer cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:23.511Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC) with EGFR mutations"},{"name":"Advanced or metastatic NSCLC"}]},"trialDetails":[{"nctId":"NCT07143045","phase":"","title":"A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases","status":"RECRUITING","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2025-12-29","conditions":"EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases","enrollment":800},{"nctId":"NCT06675695","phase":"","title":"Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-10-30","conditions":"Non Small Cell Lung Cancer","enrollment":4864},{"nctId":"NCT02411448","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2015-05-06","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":545},{"nctId":"NCT07338396","phase":"","title":"A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2026-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":3000},{"nctId":"NCT02296125","phase":"PHASE3","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-03","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer","enrollment":674},{"nctId":"NCT07271446","phase":"PHASE1","title":"An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer","status":"COMPLETED","sponsor":"Precision Biotech Taiwan Corp.","startDate":"2018-09-01","conditions":"Non-small Cell Lung Cancer","enrollment":8},{"nctId":"NCT02157883","phase":"PHASE1","title":"Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-06","conditions":"Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer","enrollment":39},{"nctId":"NCT03653546","phase":"PHASE2, PHASE3","title":"First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases","status":"COMPLETED","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2018-10-29","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases","enrollment":492},{"nctId":"NCT07036016","phase":"","title":"Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2015-01-01","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":67818},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":"Non-Small Cell Lung Cancer","enrollment":5279},{"nctId":"NCT02424617","phase":"PHASE1, PHASE2","title":"A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2015-04-19","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT06071013","phase":"PHASE1, PHASE2","title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2024-02-23","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation","enrollment":20},{"nctId":"NCT02588261","phase":"PHASE3","title":"A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-02-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":530},{"nctId":"NCT04322890","phase":"PHASE2","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-04-16","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation","enrollment":6000},{"nctId":"NCT04401059","phase":"PHASE4","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","status":"RECRUITING","sponsor":"Tian Xie","startDate":"2020-11-09","conditions":"Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma","enrollment":744},{"nctId":"NCT03647592","phase":"","title":"Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Hunan Province Tumor Hospital","startDate":"2018-06-01","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04397432","phase":"","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tian Xie","startDate":"2020-08-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":878},{"nctId":"NCT05934461","phase":"","title":"A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer","status":"COMPLETED","sponsor":"Laibin People's Hospital","startDate":"2014-12-01","conditions":"The Primary Study Metric is Progression-free Survival (PFS)","enrollment":48},{"nctId":"NCT05445791","phase":"PHASE3","title":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2021-07-15","conditions":"Non Small Cell Lung Cancer","enrollment":312},{"nctId":"NCT04179890","phase":"","title":"The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-12-17","conditions":"Non-squamous, Non-Small Cell Lung Cancer","enrollment":462},{"nctId":"NCT02805530","phase":"NA","title":"Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-06","conditions":"Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms","enrollment":36},{"nctId":"NCT01994057","phase":"","title":"A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2012-09","conditions":"Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation","enrollment":1000},{"nctId":"NCT01570296","phase":"PHASE1","title":"A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2011-10-03","conditions":"Non-Small Cell Lung Cancer, Solid Tumors","enrollment":38},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT00522145","phase":"PHASE2","title":"Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib","status":"COMPLETED","sponsor":"Kadmon Corporation, LLC","startDate":"2007-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":41},{"nctId":"NCT03239015","phase":"PHASE2","title":"Efficacy and Safety of Precision Therapy in Refractory Tumor","status":"UNKNOWN","sponsor":"Baodong Qin","startDate":"2017-01-01","conditions":"Rare Tumor, Refractory Tumor","enrollment":300},{"nctId":"NCT01288430","phase":"PHASE1","title":"A Study of DS-2248 in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2011-03-29","conditions":"Solid Tumors, Non-small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT02736513","phase":"PHASE2","title":"Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2016-05","conditions":"Lung Cancer","enrollment":40},{"nctId":"NCT03382795","phase":"PHASE2","title":"Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2018-01-03","conditions":"EGFR Positive Non-small Cell Lung Cancer","enrollment":63},{"nctId":"NCT04874844","phase":"PHASE2, PHASE3","title":"JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety","status":"UNKNOWN","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2021-07-30","conditions":"NSCLC","enrollment":420},{"nctId":"NCT01610336","phase":"PHASE2","title":"A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04-05","conditions":"Non-small Cell Lung Cancer","enrollment":161},{"nctId":"NCT03595644","phase":"PHASE2","title":"Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2017-02-12","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":74},{"nctId":"NCT02747953","phase":"PHASE2","title":"Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-07","conditions":"Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT02893332","phase":"PHASE3","title":"Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)","status":"TERMINATED","sponsor":"Sichuan Provincial People's Hospital","startDate":"2016-01-15","conditions":"Stage IV EGFR Mutated Non-Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT01556191","phase":"PHASE2","title":"Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2012-05-15","conditions":"Stage IV Lung Cancer","enrollment":379},{"nctId":"NCT02762877","phase":"","title":"Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Genomic Health®, Inc.","startDate":"2016-04","conditions":"Non Small Cell Lung Carcinoma","enrollment":140},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT04575415","phase":"","title":"Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-10-07","conditions":"NSCLC","enrollment":272},{"nctId":"NCT00553254","phase":"PHASE2","title":"Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02-05","conditions":"Carcinoma, Non Small Cell Lung","enrollment":55},{"nctId":"NCT04115410","phase":"","title":"PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-07-01","conditions":"Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events","enrollment":4724},{"nctId":"NCT03119519","phase":"PHASE2","title":"Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.","status":"UNKNOWN","sponsor":"Southern Medical University, China","startDate":"2017-12-11","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":148},{"nctId":"NCT02416739","phase":"PHASE2, PHASE3","title":"Anticancer Activity of Nicotinamide on Lung Cancer","status":"UNKNOWN","sponsor":"Il Yeong Park, Ph.D.","startDate":"2015-03","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":110},{"nctId":"NCT02745691","phase":"","title":"Psychometric Properties of the EORTC QLQ-LC29","status":"COMPLETED","sponsor":"University Hospital Regensburg","startDate":"2016-04-01","conditions":"Lung Cancer","enrollment":523},{"nctId":"NCT04193007","phase":"PHASE2","title":"The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2019-12-01","conditions":"Non Small Cell Lung Cancer, Brain Metastases","enrollment":100},{"nctId":"NCT03529084","phase":"PHASE3","title":"Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2018-07-24","conditions":"Carcinoma, Non-small Cell Lung","enrollment":""},{"nctId":"NCT04007835","phase":"NA","title":"Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2019-07","conditions":"NSCLC","enrollment":120},{"nctId":"NCT02889692","phase":"PHASE3","title":"Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2013-03","conditions":"Cancer","enrollment":23},{"nctId":"NCT02142036","phase":"PHASE2","title":"N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2014-05","conditions":"Metastatic Cancer","enrollment":50},{"nctId":"NCT03799094","phase":"PHASE1, PHASE2","title":"Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations","status":"UNKNOWN","sponsor":"Clifford Hospital, Guangzhou, China","startDate":"2018-12-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":150},{"nctId":"NCT01967095","phase":"PHASE1","title":"Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-10-15","conditions":"EGFR-Mutant Lung Cancer","enrollment":53},{"nctId":"NCT03720873","phase":"PHASE2","title":"EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2018-10","conditions":"EGFR Gene Mutation","enrollment":90},{"nctId":"NCT00266877","phase":"PHASE2","title":"Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2005-12","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Neoplasms","enrollment":172},{"nctId":"NCT03461185","phase":"PHASE2","title":"Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2018-05-01","conditions":"Non Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT03053297","phase":"","title":"Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":89},{"nctId":"NCT03389256","phase":"PHASE2","title":"Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2018-12-30","conditions":"Lung Diseases, Neoplasms, Respiratory Tract Diseases","enrollment":144},{"nctId":"NCT02714010","phase":"PHASE3","title":"EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Non-Small Cell Lung Cancer","enrollment":601},{"nctId":"NCT01098500","phase":"","title":"Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Cancer","enrollment":3800},{"nctId":"NCT01256437","phase":"PHASE2","title":"Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream, for EGFR'I Induced Acneiform Rash","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2011-01","conditions":"Acneiform Rash","enrollment":90},{"nctId":"NCT01965275","phase":"PHASE2","title":"High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs","status":"UNKNOWN","sponsor":"Anhui Medical University","startDate":"2013-10","conditions":"Self Efficacy, Drug Toxicity","enrollment":20},{"nctId":"NCT03123484","phase":"PHASE2","title":"β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2017-04","conditions":"Non Small Cell Lung Cancer","enrollment":80},{"nctId":"NCT01085136","phase":"PHASE3","title":"LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1154},{"nctId":"NCT03071705","phase":"NA","title":"Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2016-03","conditions":"Non-Small Cell Adenocarcinoma, Tyrosine Kinase Mutation, EGFR Gene Mutation","enrollment":120},{"nctId":"NCT01024413","phase":"PHASE3","title":"Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations","status":"COMPLETED","sponsor":"Chinese Society of Lung Cancer","startDate":"2009-07","conditions":"Thoracic Neoplasms","enrollment":256},{"nctId":"NCT03050411","phase":"PHASE1","title":"Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2016-05","conditions":"Nonsmall Cell Lung Cancer","enrollment":30},{"nctId":"NCT02787447","phase":"PHASE2","title":"Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2016-05","conditions":"Lung Adenocarcinoma","enrollment":46},{"nctId":"NCT02906163","phase":"PHASE1, PHASE2","title":"First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy","status":"UNKNOWN","sponsor":"SciClone Pharmaceuticals","startDate":"2016-10","conditions":"EGFR Mutation Positive Non Small Cell Lung Cancer","enrollment":188},{"nctId":"NCT02882984","phase":"PHASE3","title":"Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)","status":"UNKNOWN","sponsor":"Sichuan Provincial People's Hospital","startDate":"2015-03","conditions":"Stage IV EGFR Mutated NSCL With Brain Metastases","enrollment":325},{"nctId":"NCT02013089","phase":"NA","title":"A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-12","conditions":"Gastrointestinal Cancers","enrollment":50},{"nctId":"NCT00656136","phase":"PHASE3","title":"BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":585},{"nctId":"NCT01745302","phase":"","title":"Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma","status":"UNKNOWN","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2011-11","conditions":"Cancer","enrollment":470},{"nctId":"NCT02788058","phase":"PHASE2","title":"A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2016-05","conditions":"Lung Adenocarcinoma, EGFR Positive Non-small Cell Lung Cancer","enrollment":76},{"nctId":"NCT02031601","phase":"PHASE4","title":"Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2014-01","conditions":"Non-Small-Cell Lung Cancer","enrollment":250},{"nctId":"NCT02701231","phase":"NA","title":"Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-11","conditions":"Lung Neoplasms","enrollment":200},{"nctId":"NCT00570401","phase":"PHASE2","title":"Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-06","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT01189435","phase":"PHASE2","title":"Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08","conditions":"Lung Cancer","enrollment":2},{"nctId":"NCT01121575","phase":"PHASE1","title":"A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Non Small Cell Lung Cancer","enrollment":70},{"nctId":"NCT01167244","phase":"PHASE2","title":"Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-08","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":11},{"nctId":"NCT00993499","phase":"PHASE1","title":"Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-10","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":44},{"nctId":"NCT01090011","phase":"PHASE1","title":"Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":171},{"nctId":"NCT02321293","phase":"PHASE1","title":"A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC","status":"UNKNOWN","sponsor":"Lady Davis Institute","startDate":"2015-08","conditions":"Lung Cancer","enrollment":20},{"nctId":"NCT01580735","phase":"PHASE2","title":"ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2012-05","conditions":"Non-small-cell Lung Cancer","enrollment":40},{"nctId":"NCT02405247","phase":"","title":"TAURAS - T790 AURA ScreenFailure SOC Registry Study","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2015-06","conditions":"Non Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT01928160","phase":"PHASE2","title":"Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib","status":"WITHDRAWN","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2014-06","conditions":"Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT01955421","phase":"PHASE2","title":"Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-07","conditions":"Advanced Stage Non Small Cell Lung Cancer","enrollment":224},{"nctId":"NCT01602289","phase":"PHASE1","title":"A Study of LY2875358 in Japanese Participants With Advanced Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-06","conditions":"Solid Tumors, Lymphoma, Carcinoma, Non-Small-Cell Lung","enrollment":17},{"nctId":"NCT00711594","phase":"PHASE2","title":"LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":74},{"nctId":"NCT01514877","phase":"PHASE2","title":"Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2012-01","conditions":"Lung Cancer, Metastatic Cancer","enrollment":20},{"nctId":"NCT01861223","phase":"PHASE1, PHASE2","title":"Afatinib Plus Nimotuzumb for NSCLC","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2013-05","conditions":"NSCLC","enrollment":50},{"nctId":"NCT00717847","phase":"","title":"A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2006-02","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT01932229","phase":"PHASE2","title":"An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2013-02","conditions":"NSCLC","enrollment":20},{"nctId":"NCT00955695","phase":"PHASE3","title":"Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2009-05","conditions":"Lung Cancer","enrollment":242},{"nctId":"NCT01776684","phase":"NA","title":"Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2012-06","conditions":"EGFR Mutation Positive Non-small Cell Lung Cancer","enrollment":200},{"nctId":"NCT01158170","phase":"PHASE3","title":"Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2010-06","conditions":"Non-small Cell Lung Cancer","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EGFR-TKI"],"phase":"phase_3","status":"active","brandName":"Erlotinib /Gefitinib","genericName":"Erlotinib /Gefitinib","companyName":"Zhejiang Cancer Hospital","companyId":"zhejiang-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Erlotinib and gefitinib are tyrosine kinase inhibitors that block epidermal growth factor receptor (EGFR) signaling to inhibit cancer cell proliferation. Used for Non-small cell lung cancer (NSCLC) with EGFR mutations, Advanced or metastatic NSCLC.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}